PDE5A
cGMP-specific 3',5'-cyclic phosphodiesterase
As of the edition of 20 October 2026, PDE5A (cGMP-specific 3',5'-cyclic phosphodiesterase, UniProt O76074) has 14 drugs tested at it and 19 companies on the list, 3 on route A and 9 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O76074
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 52
- Disease areas
- Urinary and reproductive; Mental health; Lungs and airways; Heart and blood vessels; Nervous system; Inherited and neonatal; Nutrition and metabolism; Cancer
- Registered trials of its drugs
- 590
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 6 |
| Active | 3 |
| Went quiet | 4 |
| Stopped | 1 |
| Total | 14 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Sildenafil | Marketed | Phase 4 | Ends 2030 |
| Tadalafil | Marketed | Phase 4 | none listed |
| Vardenafil | Marketed | Phase 4 | none listed |
| Udenafil | Marketed | Phase 4 | none listed |
| Avanafil | Marketed | Phase 4 | none listed |
| Ibudilast | Marketed | Phase 3 | none listed |
| TPN171H | Active | Phase 3 | none listed |
| Mirodenafil | Went quiet | Phase 3 | none listed |
| PF-00489791 | Went quiet | Phase 2 | none listed |
| Gisadenafil | Went quiet | Phase 2 | none listed |
| SLx-2101 | Went quiet | Phase 2 | none listed |
| DKF-313 | Active | Phase 3 | none listed |
12 of 14 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 9 |
| Engaged | 6 |
| Undetermined | 1 |
| Total on the list | 19 |
The other 16 companies at PDE5A
In the product19 companies in all; 16 are not named here, and no score is.
See the 19 companies at PDE5A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.